Menu
GWAS Study

Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors.

Trendowski MR, Wheeler HE, El-Charif O et al.

32998964 PubMed ID
GWAS Study Type
300 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

TM
Trendowski MR
WH
Wheeler HE
EO
El-Charif O
FD
Feldman DR
HR
Hamilton RJ
VD
Vaughn DJ
FC
Fung C
KC
Kollmannsberger C
EL
Einhorn LH
TL
Travis LB
DM
Dolan ME
Chapter II

Abstract

Summary of the research findings

Purpose: Cisplatin is a first-line chemotherapeutic for many cancers, but causes neurotoxicity including hearing loss, tinnitus, and peripheral sensory neuropathy. However, no study has comprehensively characterized risk factors for developing multiple (>1) severe neurotoxicities.

104 European ancestry cases, 196 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

300
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
U.K., Canada, U.S.
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.